ARTICLE
27 October 2014

FDA Determines LUPRON DEPOT Not Withdrawn For Safety Or Effectiveness Reasons

JD
Jones Day

Contributor

Jones Day is a global law firm with more than 2,500 lawyers across five continents. The Firm is distinguished by a singular tradition of client service; the mutual commitment to, and the seamless collaboration of, a true partnership; formidable legal talent across multiple disciplines and jurisdictions; and shared professional values that focus on client needs.
FDA published its determination that LUPRON DEPOT, an injectable vial containing 3.75 milligrams of the drug, was not withdrawn from sale for reasons of safety or effectiveness.
United States Food, Drugs, Healthcare, Life Sciences

In the October 8, 2014, Federal Register, FDA published its determination that LUPRON DEPOT (leuprolide acetate for depot suspension), an injectable vial containing 3.75 milligrams of the drug, was not withdrawn from sale for reasons of safety or effectiveness.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More